TSLP, is a key upstream regulator of multiple inflammatory cascades (including IL-4, IL-5, IL-13, and IgE). Tezepelumab’s inhibition of TSLP reduces airway inflammation, exacerbations, and improves lung function. Its broad mechanism addresses both eosinophilic and non-eosinophilic asthma phenotypes, offering a therapeutic option for a wide range of severe asthma patients.